Bracco S.p.A.

01/27/2026 | Press release | Archived content

The European Commission extended the Marketing Authorisation for VUEWAY (gadopiclenol) in the European Union for use in pediatric patients under 2 years of age

Expanded EU approval reflects positive benefit-risk ratio of VUEWAY® in children from birth

Bracco S.p.A. published this content on January 27, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 20, 2026 at 15:39 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]